Ethris Ethris is a biopharmaceutical company focused on developing therapies for pulmonary diseases such as primary ciliary dyskinesia. | Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. | Ocugen Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases | ![]() Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. | |
Founding Date | Founding Date 2009 | Founding Date 2003 | Founding Date 2013 | Founding Date 2001 |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Planegg, DE HQ | Locations San Diego, US HQ | Locations Malvern, US HQ | Locations Chapel Hill, US HQ Roslin, GB |
Employees | Employees 504% decrease | Employees 70 | Employees 84425% increase | Employees 5172% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 292.1 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) $4.4m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income N/A | Net income ($78m) (FY, 2022) | Net income ($67.8m) (FY, 2025) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 347.9m | Total funding raised N/A | Total funding raised $ 235m |
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyOcugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases
View company
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View company